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SUMMARY   
 
Multiple myeloma (MM) is a malignancy of plasma cells that largely remains incurable. 
The search for new therapeutic targets is therefore essential. Here we show that a 
higher expression of the lysine methyltransferase SETD8, which is responsible for 
histone H4K20 mono-methylation, is an adverse prognosis factor associated with a poor 
outcome in two cohorts of newly diagnosed patients. Remarkably, primary malignant 
plasma cells are particularly addicted to SETD8 activity. Indeed, pharmacological 
inhibition of this enzyme by the chemical compound UNC0379 demonstrated a 
significantly higher toxicity in MM cells compared to normal cells from the bone marrow 
microenvironment. Moreover, RNA sequencing and functional studies revealed that 
SETD8 inhibition induces a mature non-proliferating plasma cell signature and an 
activation of the p53 canonical pathway, which together leads to an impairment of 
myeloma cell proliferation and survival. However, UNC0379 treatment triggers a deadly 
level of replicative stress in p53 deficient MM cells, indicating that the cytotoxicity 
associated with SETD8 inhibition is independent of the p53 status. Consistent with 
this, the combination of UNC0379 with the conventional cytotoxic agent melphalan 
strongly enhances DNA damage and overcomes drug resistance in myeloma cells. 
Thus, targeting SETD8 could be of therapeutic interest to improve MM treatment in high-
risk patients independently of the p53 status. 
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INTRODUCTION 
 
 Multiple Myeloma (MM) is a cancer of terminally differentiated plasma cells 
characterized by bone destruction, renal failure, and anemia1. It is the second most 
common hematological malignancy after non-Hodgkin lymphoma2. Over the past 15 
years, several advances in treatments have led to a significantly higher survival of 
intensively treated patients. This involves a large panel of therapeutic agents, including 
immunomodulatory drugs and proteasome inhibitors, in combination with autologous 
stem cell transplantation, alkylating agents (melphalan) and glucocorticoids3. 
Unfortunately, despite the recent progress in MM treatments, most patients will 
ultimately relapse and develop drug resistance. This cancer thus remains incurable for 
the majority of patients. 
 In addition to a wide panel of genetic mutations, recent studies have pinpointed 
that epigenetic alterations, including aberrant DNA and histone methylation, might be 
also important players in multiple myeloma development4. These recent findings could 
illuminate new mechanisms central to the genesis of multiple myeloma and offer the 
possibility to reveal novel approaches and targets for effective therapeutic intervention. 
For example, the inhibition of the histone H3K27 methyltransferase EZH2 has recently 
emerged as a potential strategy for the treatment of myeloma5. Moreover, classic 
epigenetic modulating agents, such as histone decatylase inhibitors and DNA 
methyltransferase inhibitors, are already tested in as monotherapy or in combination 
with conventional anti-MM agents6,7. However, the occurrence of important side effects 
and the appearance of resistance to these drugs increase the need to identify novel 
epigenetic targets in multiple myeloma and evaluate their pre-clinical perspective. 
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SETD8 (also known as SET8, PR-Set7, KMT5A) has been identified as the 
epigenetic enzyme responsible for the mono-methylation of histone H4 at lysine 20 
(H4K20me1) 8. SETD8 and H4K20me1 are naturally increased during mitosis and play a 
critical role in chromatin compaction, gene regulation and cell-cycle progression8–1010. In 
addition, SETD8 could induce the methylation of non-histone proteins, such as the 
replication factor PCNA and the tumor suppressor p53 11,12. While SETD8-mediated 
methylation of p53 inhibits apoptosis12, PCNA methylation by SETD8 might enhance the 
interaction with the Flap endonuclease FEN1 and promote cell proliferation11. 
Consistent with this, the overexpression of SETD8 has been reported in many different 
solid tumors14–17 and pharmacological inhibition of SETD8 is sufficient to activate the 
p53 pro-apoptotic program in neuroblastoma cell lines18. This has suggested that this 
enzyme could be an attractive target to rescue p53 functions in cancers displaying a low 
incidence of p53 genetic alterations, as it is the case at early stages in multiple 
myeloma19. However, the role of SETD8 and its incidence in the development of 
multiple myeloma or any hematological malignancies is not known. 
 Here, we provide evidence that malignant plasma cells are addicted to SETD8 
expression, which is associated with a poor outcome independently of changes in the 
steady state level of histone H4K20me1. Although inducing p53 canonical pathway, we 
show that the pharmacological inhibition of SETD8 by the chemical compound 
UNC0379 also triggers cell-cycle defects and apoptosis in myeloma cells deficient for 
p53. Finally, the combination of UNC0379 with the cytotoxic agent melphalan strongly 
enhances DNA damage and overcomes drug resistance, suggesting that targeting 
SETD8 activity could be beneficial to improve multiple myeloma treatment in high-risk 
patients independently of their mutational status for p53. 
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RESULTS 
 
 
SETD8 up-regulation in myeloma is associated with a poor outcome.  In order to 
identify epigenetic factors potentially involved in Multiple Myeloma, we used public 
affymetrix microarrays gene expression data sets to identify which genes encoding 
histone-modifying enzymes are differentially expressed between normal bone marrow 
plasma cells (BMPCs, n=22), purified primary MM cells from newly diagnosed patients 
(MMCs, n = 345) and human myeloma cell lines (HMCLs, N=42)19. As shown in Figure 
1A, a significant higher levels of mRNAs encoding the histone H4K20 mono-
methyltransferase SETD8 was found in HMCLs compared to BMPCs and MMCS (Fig 
1A). Furthermore, although we did not observe a statistical difference with BMPCs, 
SETD8 mRNA levels appeared heterogeneous in MMCs (Figure 1A) ranging from 65 to 
63338 in affymetrix signal. This contrasted SETD8 mRNA levels was not restrained to a 
particular MM molecular sub-type (supplementary Figure S1). Consistent with these 
observations, immunoblot analysis with specific SETD8 antibody showed that HMCLs 
and some MMCs displayed higher SETD8 protein levels compared with non-cancerous 
plasma cells (PC) (Figure 1B). These higher SETD8 protein levels were independent to 
the natural cell-cycle fluctuation of the enzyme9, as the levels of the mitotic marker 
histone H3-S10 phosphorylation were relatively similar in all tested samples (Figure 1B). 
SETD8 is known as the unique enzyme responsible for the mono-methylation of histone 
H4 at lysine 20 (H4K20me1)8. Yet, the levels of H4K20me1 remained roughly 
unchanged in HMCLs and MMCs displaying higher SETD8 levels (Figure 1B), indicating 
that SETD8 up-regulation does not trigger an increase in the steady state level of 
histone H4K20me1 in multiple myeloma.  
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 We next investigated the prognostic value of SETD8 up-regulation in two 
independent cohorts of previously untreated MM patients (UAMS-TT2 n=256 and 
UAMS-TT3 n=158 cohorts), using Maxstat R algorithm. High SETD8 mRNA levels were 
predictive of both shorter event free survival and overall survival in the two cohorts 
(Figure 1C). Consistent with these results, SETD8 mRNA levels were significantly 
increased in patients harboring Chr1q21 gain (Figure 1D) or presenting a high gene 
expression-based proliferation index (GPI) (Figure 1E), molecular features being 
associated with a poor outcome in MM patients. However, SETD8 expression did not 
correlate with MMC plasma cell labeling index (PCLI) in a cohort of 101 newly 
diagnosed patients (supplementary Figure S2), suggesting that SETD8 up-regulation 
is likely not a hallmark of MMC proliferation status. Gene set expression analysis 
(GSEA) of patients with high SETD8 expression highlighted a significant enrichment of 
genes involved in IRF4 targets, MYC-MAX targets, MAPK pathway and DNA repair 
(Supplementary Figure S3, P<0.001), suggesting that SETD8 up-regulation correlates 
with changes in signaling pathways involved in MM pathophysiology. Furthermore, 
SETD8 expression is significantly higher in MM cell of patients at relapse compared to 
newly diagnosed patients, underlining a potential role of SETD8 in drug resistance 
(Supplementary Figure S4). Altogether, these data reveal that SETD8 is 
overexpressed in myeloma and this up-regulation is associated with a poor outcome 
and deregulation of major signaling pathways in MM patients. 
 
UNC0379-mediated SETD8 inhibition leads to cell-cycle defects and apoptosis in 
MMCs. To determine the biological significance of SETD8 up-regulation in MM 
pathophysiology, the effects of the small-molecule SETD8 inhibitor UNC0379 were 
examined in eight different HMCLs representative of the disease. UNC0379 is a well-
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characterized substrate-competitive inhibitor selective for SETD815,18,22. As shown in 
Figure 2A, UNC0379 treatment was sufficient to inhibit the growth of all HMCLs in a 
dose dependent manner with an average half maximal inhibitory concentration (IC50) 
ranging from 1.25 to 6.3 µM (Figure 2A). To determine the molecular mechanisms of 
this HMCL growth inhibition, the effects of UNC0379 treatment on SETD8 activity, cell 
proliferation and survival were examined using immunoblot and flow cytometry assays in 
XG7 and XG25 MM cell lines, which displayed similar IC50 values for UNC0379. As 
shown in Figure 2B, analysis of whole cell extracts after 24 hours of treatment showed a 
strong decrease in H4K20me1, but not of SETD8 and histone H4, thereby 
demonstrating the rapid and efficient inhibition of SETD8 activity (Figure 2B). In the 
following hours, this SETD8 inhibition was associated with cell-cycle defects, as shown 
by an accumulation in G1 phase and a decrease in DNA replication (S) phase 48 hours 
after treatment (Figure 2C). At later time points, these cell cycle defects was followed by 
the activation of apoptosis, as measured by the appearance of 33% and 26% of 
annexin-V positive XG7 and XG25 cells (Figure 2D).  
 To confirm that SETD8 is essential for growth and viability of malignant plasma 
cells, bone marrow (BM) from MM patient samples were cultured with recombinant 
interleukin 6 in presence or not of UNC0379. Five days after treatment, the percentage 
of myeloma and non-myeloma cells was then measured by flow cytometry after staining 
with anti-CD138 antibody that specifically recognizes plasma cells. As shown in Figure 
2E, the median number of CD138 positive malignant plasma cells were decreased in a 
dose-dependent manner, with 50% and 63% of reduction with 2.5 µM and 5 µM of 
UNC0379 respectively (P = 0.001 and P < 0.0001; N=8), whereas non-tumoral BM cells 
were less sensitive with a decrease of 26% and 24% at these UNC0379 concentrations. 
In addition, to support the feasibility of preclinical studies with SETD8 inhibitors, primary 
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5T33vv murine MM models23 were treated with growing concentrations of UNC0379 for 
24h hours before cell viability analysis. As observed with human primary MM cells 
(Figure 2E), UNC0379 treatment results in significant reduction of 5T33vv viability in a 
dose dependent manner (Supplementary Figure S5). We therefore conclude that 
malignant plasma cells are particularly addicted to SETD8 activity and that the 
pharmacological inhibition of this epigenetic enzyme is highly toxic, leading rapidly to 
cell growth inhibition and apoptosis. 
	  
SETD8 inhibition impairs MM cell proliferation together with activation of p53 
target gene pathways. SETD8 has been involved in all nuclear processes that use 
DNA as a matrix, including a critical role in the regulation of gene expression8. In order 
to gain insights into the mechanisms contributing to SETD8-mediated MM cell growth 
inhibition and death, we therefore performed transcriptome analysis in XG7 and XG25 
HMCLs after SETD8 inhibition using RNA sequencing (RNAseq). To identify gene 
expression alterations caused by SETD8 inhibition in HMCLs, we isolated total RNAs 18 
hours after UNC0379 treatment or 48 hours after shRNA-induced SETD8 silencing, 
when H4K20me1 decrease did not trigger DNA replication defects yet24,25. A common 
signature of 820 up-regulated genes and 360 down-regulated genes was found in 
UNC0379-treated and SETD8-depleted cell lines compared to the untreated and shRNA 
control cell lines (Fold change > 2; FDR ≤ 0.05) (supplementary figure S6 and 
Supplementary Table 1). Gene Set Enrichment Analysis (GSEA) identified, as the 
most down-regulated pathways, genes involved in cell-cycle, stem cells, proliferating 
plasmablasts and MM proliferating molecular subgroup together with genes repressed 
upon loss of the histone H3K27 methyltransferase EZH2 (Figures 3A and 3B). 
Conversely and consistent with the presence of a functional p53 in XG7 and XG25 cell 
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lines, a significant positive enrichment was found for p53 target genes, including p21 
and GADD45A genes, and genes overexpressed in mature BMPCs versus 
plasmablasts (Figures 3C and 3D). A positive enrichment for genes normally down-
regulated by c-MYC, EZH2, DNA methylation or histone deacetylases (HDAC) was also 
observed (Figure 3C), which might suggest some impairments of chromatin silencing 
pathways upon SETD8 inhibition in MM cells. As shown in figure 3E, immunoblot 
analysis of UNC0379-treated XG7 HMCLs confirmed the increased levels of p53 and 
p21 proteins upon UNC0379 treatment. However, we did not observe a significant 
phosphorylation of the histone variant H2A.X (Figure 3E), suggesting p53 activation in 
XG7 MM cells treated with UNC0379 occurs in absence or low level of DNA damage. 
Altogether, these results data indicate that the cytotoxic effects of SETD8 inhibition in 
p53-proficient HMCLs are associated with mature non-proliferating plasma cell 
transcriptional signature and activation of the p53 canonical pathway.  
 
The cytotoxicity of UNC0379 treatment is not dependent on p53 in malignant 
plasma cells. Previous studies showed that UNC0379-induced cell death depends on 
the activation of p53 in neuroblastoma cancer models (NB), thereby rending p53-
deficient NB cells more resistant to SETD8 inhibition (Veschi et al. 2017). To determine 
whether the cytotoxic effects of the pharmacological inhibition of SEDT8 mediated by 
UNC0379 was also dependent on p53 activation in MM cells, we compared the 
UNC0379 response in p53 wild-type HMCLs (n=7) and p53-deficient HMCLs (n=5)20,21 
that displayed similar SETD8 expression levels (Figure 4A). Noted of, there was no 
significant correlation between SETD8 and P53 expression in HMCLs (Supplementary 
Figure S7). Although IC50 values for p53-deficient HMCLs following UNC0379 treatment 
were more heterogeneous, we found no statistical difference with the group of p53 wild-
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type HMCLs (Figure 4B). We also observed no statistical difference in the IC50 values of 
UNC0379 according to the expression levels p53 in HMCLs, whatever their p53 status 
(Supplementary Figure S8). Altogether, these results suggested that the absence of a 
functional p53 did not alter the sensitivity of malignant plasma cells to the 
pharmacological inhibition of SETD8 activity. To verify this hypothesis and gain insights 
into the mechanisms by which UNC0379 could impair the viability of malignant plasma 
cells independently of p53, we examined by immunoblot and flow cytometry analysis the 
cytotoxic effects of UNC0379 treatment on p53-proficient XG7 HMCL transduced with 
high-titer of lentivirus encoding either a p53 shRNA or an irrelevant control shRNA. Both 
cell lines showed similar IC50 values for UNC0379 (3.7 µM in control shRNA and 4.8 µM 
in P53 shRNA expressing cells). Immunoblot analysis confirmed the efficient p53 
depletion in p53 shRNA XG7 HMCL relative to control cells (Figure 4C). Consistent with 
results in Figure 3E, UNC0379 treatment led to an up-regulation of p53 without 
detectable DNA damage in shRNA control XG7 cells (Figure 4C). In contrast, higher 
levels of DNA damage and replicative stress were observed in UNC0379-treated XG7 
cells depleted for p53, as evidenced by the increased levels of both phosphorylated 
histone variant H2A.X and checkpoint protein CHK1 (Figure 4C) and by an 
accumulation of cells in G2/M phase of the cell cycle (Figure 4D). This was followed by 
the appearance of a high percentage of apoptotic cells, similarly to the percentage 
detected in UNC0379-treated control shRNA XG7 cells displaying p53 activation (Figure 
4E). Importantly, a similar DNA damage signature was observed in XG1 HMCL naturally 
harboring a mutated inactive p53 (Supplementary Figure S9). Thus, these results 
indicated that UNC0379-induced cytotoxicity in MM cells is independent on p53 status 
and that a high level of SETD8 likely protects MM cells from spontaneous intrinsic DNA 
damage and replicative stress.  
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Pharmacological inhibition of SETD8 synergizes with melphalan. The results 
presented above indicate that the pharmacological inhibition of SETD8 could constitute 
a promising strategy to improve multiple myeloma treatment by increasing DNA damage 
and genomic instability. To further explore this possibility, we investigated whether 
SETD8 inhibition could enhance the cytotoxicity of melphalan and overcome resistance 
to this alkylating agent widely used in MM treatment. To this end, we first measured by 
FACS the levels of apoptotic cells in sensitive (MelphS) and melphalan-resistance 
(MelphR) XG7 MM cell lines treated with either 5 µM of melphalan, 3 µM of UNC0379 or 
a combination of the two compounds. Note of, the levels of SETD8 and TP53 
expression levels were similar in both cell lines (Supplementary Figure S10). Whereas 
UNC0379 alone slightly increased the percentage of annexinV-positive MelphS and 
MelphR cells, the combination with Melphalan significantly enhanced this percentage in 
MelphR cells and, to a lesser extent, in MelphS cells (Figure 5A). Remarkably, the 
overcome resistance to melphalan upon UNC0379 treatment in MelpR cells was 
associated with an enhancement of DNA breaks, as observed by a higher level of 
phosphorylated histone variant H2AX and by an increase in the number of DNA 
damage-induced 53BP1 foci in these cells (Figures 5B and 5C). However, although we 
observed an activation of the cell-cycle checkpoint p21 (Figure 5C), UNC0379 
sensitized HMCLs to melphalan treatment was independently from the presence of p53 
(Figure 5D). Altogether, these results indicate that a low dose of UNC0379 is sufficient 
to significantly increase the percentage of melphalan-induced MM cell death in a p53 
dependent manner and to overcome resistance to this alkylating agent, thereby 
demonstrating the therapeutic interest to target SETD8-mediated lysine methylation in 
multiple myeloma whatever their p53 status.  
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DISCUSSION 
 
 This study unveils for the first time a role of the lysine methytransferase SETD8 in 
multiple myeloma (MM) patho-physiology and drug resistance. We have shown that 
elevated levels of SETD8 are associated with a poor prognosis in two large cohorts of 
newly diagnosed patients and correlates with the deregulation of regulatory nodes 
involved in multiple myeloma, including IRF4, MYC/MAX, MAPK and DNA repair 
pathways (Figure 1). Moreover, patients displaying higher SETD8 expression are 
associated with specific molecular features, such as increase copy of Chr1q21 or a high 
GPI index (Figure 1). Consistent with this, primary MM cells are particularly addicted to 
SETD8 activity and the recently developed small-molecule inhibitor of SETD8, 
UNC0379, demonstrated a significantly higher toxicity in MM cells compared to normal 
cells from the bone marrow microenvironment (Figure 2). From a mechanistic point of 
view, our RNA-seq results show that the genetic or pharmacological inhibition of SETD8 
in MM cell lines results in the activation of a mature non-proliferating plasma cell 
signature and of the p53 canonical pathway (Figure 3). However, UNC0379-induced 
cytotoxicity does not necessarily require p53 activation as p53 wild-type and deficient 
MM cells display similar sensitivity to SETD8 inhibition (Figures 3 and 4). Finally, in 
order to support future pre-clinical study, we have shown that a low dose of UNC0379 
enhances melphalan-induced cell death and overcomes the resistance associated with 
this DNA-damaging conventional cytotoxic agent in both p53 wild-type and deficient MM 
cells (Figure 5). Altogether, these results provide evidence for SETD8 inhibition as a 
potential novel therapeutic strategy in multiple myeloma independently from the 
mutational p53 status of these tumors.  
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 An up-regulation of SETD8 is not specific to multiple myeloma, as it has also 
been observed in different types of solid tumors11, such as papillary thyroid cancer16, 
breast carcinoma14,26, and childhood tumors of the nervous system15,18. However, the 
mechanisms that contribute to elevated levels of SETD8 in cancer still remained 
unclear. In neuroblastoma, a higher-level of SETD8 could be due in part to DNA copy-
number gains at chr12q24, the region that encompasses SETD8 encoding gene26. 
Another non-exclusive mechanism is related to the deregulation of oncogenic c-MYC 
pathway, since SETD8 encoding gene has been found as a transcriptional target of c-
MYC27 and functionally required to mediate MYC-induced cell growth15. It is widely 
established that c-MYC is a key regulator in MM with deregulations related to 
translocations, gains and amplification, mutations in RAS genes and MYC transcription 
or translation activation28. Interestingly, while chr12q24 gains are not present in 
myeloma, we identified here a significant enrichment of c-MYC/MAX target genes in MM 
patients characterized by high SETD8 expression, thereby supporting a potential role of 
this oncogenic pathway in SETD8 deregulation. Furthermore, SETD8 depletion or 
inhibition results in up-regulation of genes repressed upon c-MYC expression (Figure 
3C) suggesting that SETD8 might also participate in deregulation of c-MYC functions in 
multiple myeloma. 
 An unexpected result of our study is that the up-regulation of SETD8 in malignant 
plasma cells was not associated with significant changes in the steady state level of the 
mono-methylation of histone H4K20 (H4K20me1), the main target of SETD88. This 
result is independent from cell-cycle progression, since changes in the levels of SETD8 
do not correlate with cell proliferation (figure 1B and supplementary figure S2). One 
hypothesis is that an overexpression of the H4K20me1-specific demethylase PHF8, 
observed in many cancers including hematopoietic malignancies29,30, could attenuate 
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SETD8 activity on histone H4K2031. Thus, although we cannot rule out that some local 
changes in H4K20me1 levels may occur at specific genetic loci, our results indicate that 
the global level of this epigenetic modification is not a valuable marker of SEDT8 activity 
and functions in multiple myeloma.  
 Recent studies have suggested that the role of SETD8 in cancer might involve 
the methylation of other substrates than histone H4. Thus, Takawa et al. proposed that 
SEDT8 can methylate the proliferating cell nuclear antigen PCNA and thus favor HeLa 
cell proliferation11; but this result was never further confirmed in other cell types. 
Additionally, SETD8 can induce the mono-methylation of the tumor suppressor p53 at 
lysine 382 (p53K382), which attenuates its pro-apoptotic and growth arrest 
functions12,18. Hence, in neuroblastoma, inhibition of SETD8 by UNC0379 leads to cell 
death in a dependent p53 manner and p53K382 is important for this phenotype18. Our 
RNA-seq and functional studies in MM cells shows that the genetic or pharmacological 
inhibition of SETD8 leads to the activation of p53 pathway, which correlates with an 
increased in p53 and p21 protein levels, G1/S arrest followed by cell death. However, in 
contrast to neuroblastoma18, UNC0379-induced cytotoxicity in MM cells is not 
necessarily dependent on p53 activation and, despite several attempts, we were unable 
to detect p53K382me1 in MM cells. Few DNA breaks are generally sufficient to activate 
P53 functions32,33. Since the first impact of loss of SETD8 activity is excessive chromatin 
relaxation and progressive DNA damage after exit of mitosis34, we propose that the 
activation of p53 we detect in MM cells upon SETD8 inhibition is mainly triggered by 
cellular stresses during G1 progression. This would also explain why UNC0379-
mediated SETD8 inhibition is very toxic in P53-deficient MM cells, where the absence of 
a functional p53-mediated G1 arrest allows damaged cells to pursue into S-phase and 
accumulate a deadly level of DNA breaks, likely caused by improper replication fork 
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/776930doi: bioRxiv preprint first posted online Sep. 20, 2019; 
	   15	  
progression24. Altogether, our findings are consistent with a model in which UNC0379-
mediated cell death is triggered by p53 activation in p53-proficient MM cells and rather 
associated with high replicative stress in cancer cells deficient for p53, thereby rending 
multiple myeloma sensitive to SEDT8 inhibition whatever the mutational status of p53. 
 In spite of effective therapeutic protocols developed in MM, drug resistance 
remains a major concern. In this regard, we report here that high SETD8 expression is 
associated with a poor prognosis in patients treated by high-dose melphalan and 
autologous stem cell transplantation. SETD8 expression is also significantly up-
regulated in patients at relapse compared to newly diagnosed patients. In agreement 
with this, UNC0379 treatment potentiates the cytotoxicity of melphalan and overcomes 
melphalan drug resistance in MM cells, underlining the interest to target SETD8 to 
improve the treatment of MM. Melphalan is an alkylating cytotoxic agent used in MM 
patients treated by high dose chemotherapy and hematopoietic stem cell autograft and 
in non-transplantable patients, in combination with other molecules. The protective 
effect against melphalan provided by SETD8 expression is associated with the poor 
prognosis of MM patients characterized by elevated levels of SETD8. 
 Deletion of the short arm of chromosome 17 (del 17p) is associated with a poor 
outcome in MM independently of treatment regimen35–39. Interestingly, MM cell toxicity 
mediated by SETD8 inhibitor is mainly p53-independent. The frequency of events 
targeting p53 (del 17p, TP53 mutation or double hits) increases during the progression 
of MM and consecutive relapses underlining a selection of cells harboring TP53 
abnormalities in association with resistance to treatment. TP53 bi-allelic events are also 
associated with a dramatic impact on MM patients’ survival after relapse40. Therapies 
inducing significant toxicity of p53 defective MM cells are needed. Our results 
demonstrate the therapeutic interest of SETD8 inhibitor to target p53 deficient MM cells 
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by increasing replicative stress and DNA damages. Accordingly, combination of SETD8 
inhibitor with melphalan could be of clinical interest, notably in newly diagnosed patients 
presenting del17p and/or SETD8 overexpression and eligible to high dose melphalan 
and ASCT. Thus, SETD8 inhibition appears of therapeutic interest to overcome drug 
resistance and improve the treatment of MM patients at relapse independently of the 
p53 status. 
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MATERIALS AND METHODS 
 
Primary multiple myeloma cells 
Bone marrow samples were collected after patients’ written informed consent in 
accordance with the Declaration of Helsinki and institutional research board approval 
from Heidelberg and Montpellier University hospital. Bone marrow were collected from 
206 patients treated with high dose Melphalan (HDM) and autologous stem cell 
transplantation (ASCT) and this cohort is termed “Heidelberg-Montpellier” (HM) cohort. 
Patients’ MMCs were purified using anti-CD138 MACS microbeads (Miltenyi Biotec, 
Bergisch Gladbach, Germany) and their gene expression profile (GEP) obtained using 
Affymetrix U133 plus 2.0 microarrays as described41,42. The CEL files and MAS5 files 
are available in the ArrayExpress public database (E-MTAB-372). The structural 
chromosomal aberrations, as well as numerical aberrations were assayed by 
fluorescence in situ hybridization (iFISH). We also used publicly available Affymetrix 
GEP (Gene Expression Omnibus, accession number GSE2658) of a cohort of 345 
purified MMC from previously untreated patients from the University of Arkansas for 
Medical Sciences (UAMS, Little Rock, AR), termed in the following UAMS-TT2 cohort. 
These patients were treated with total therapy 2 including HDM and ASCT43. We also 
used Affymetrix data from total therapy 3 cohort (UAMS-TT3; n=158; E-TABM-1138)44 
of 188 relapsed MM patients subsequently treated with bortezomib (GSE9782) from the 
study by Mulligan et al45. The mouse 5T33MMvv	  cells originated spontaneously in aging 
C57BL/KaLwRij mice and have since been propagated in vivo by intravenous transfer of 
the diseased marrow in young syngeneic mice as described23,46. 
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Treatment of primary MM cells  
Bone marrow of patients presenting with previously untreated MM (n = 8) at the 
university hospital of Montpellier was obtained after patients’ written informed consent in 
accordance with the Declaration of Helsinki and agreement of the Montpellier University 
Hospital Centre for Biological Resources (DC-2008-417). Mononuclear cells were 
treated with or without UNC-0379 (1µM, 2.5µM or 5µM) and MMC cytotoxicity were 
evaluated using anti-CD138-phycoerythrin monoclonal antibody (Immunotech, Marseille, 
France) as described47. 
 
Human Myeloma Cell Lines (HMCLs) 
XG human myeloma cell lines (HMCLs) were cultured in the presence of recombinant 
IL-6 as previously described20. XG7 Melphalan-resistant cells were generated by 
successively treating the sensitive parental XG7 cells with 0.6µM of Melphalan for 3 
months. JJN3 was kindly provided by Dr Van Riet (Brussels, Belgium), JIM3 by Dr 
MacLennan (Birmingham, UK) and MM1S by Dr S. Rosen (Chicago, USA). AMO-1, 
LP1, L363, U266, OPM2, and SKMM2 were purchased from DSMZ (Braunsweig, 
Germany) and RPMI8226 from ATTC (Rockville, MD, USA). HMCLs were authenticated 
according to their short tandem repeat profiling and their gene expression profiling using 
Affymetrix U133 plus 2.0 microarrays deposited in the ArrayExpress public database 
under accession numbers E-TABM-937 and E-TABM-108820.  
 
Establishment of shRNA expressing HMCLs 
Control and p53 shRNA sequences were cloned in the pLenti4-EZ-mIR plasmid as 
previously described48. SETD8 and associated control shRNA sequences were cloned 
into a puromycin retroviral vector RNAi Ready pSiren as described24. Retroviral particles 
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were produced in 293FT cells. Briefly, 293FT cell line was cultured in Dulbecco's 
modified Eagle's medium and supplemented with 10% defined fetal bovine serum, 
500µg/ml geneticin, 4mM L-glutamine, and 1mM MEM sodium pyruvate. The day before 
transfection, cells were plated into a 10cm tissue culture plate to 90%-95% confluence. 
9µg of ViraPower packaging mix (Invitrogen) and 9µg of lentiviral plasmids were co-
transfected into 293FT cells using 36µl Lipofectamine 2000 reagent (Invitrogen). Forty-
eight hours later, culture supernatants were collected, concentrated 100 fold by 
ultracentrifugation (20000 g, 4 hours) and viral titers determined. Corresponding HMCLs 
were transduced with virus and stable transduced cells were obtained by adding zeocin 
(10 µg/ml) for pLenti4-EZ-mIR and puromycin (2.5µg/ml) for pSIREN viral particles. 
 
Growth assays and cell cycle analysis 
Cells were cultured for 4 days in 96-well flat-bottom microtiter plates in RPMI 1640 
medium, 10% FCS, and 2 ng/ml IL-6 (control medium) in the presence of UNC-0379. 
Cell growth was evaluated by quantifying intracellular ATP amount with a Cell Titer Glo 
Luminescent Assay (Promega, Madison, WI) using a Centro LB 960 luminometer 
(Berthold Technologies, Bad Wildbad, Germany). For cell cycle analysis, cells were 
cultured in 24-well flat-bottomed microtiter plates at 105 cells per well in RPMI1640–10% 
FCS or X-VIVO 20 culture medium with or without IL-6 (3ng/mL). The cell cycle was 
assessed using DAPI staining (Sigma-Aldrich, Saint-Louis, MO, USA) and cells in the S 
phase using incubation with bromodeoxyuridine (BrdU) for 1 h and labeling with an anti-
BrdU antibody (APC BrdU flow kit, BD Biosciences, San Jose, CA, USA) according to 
the manufacturer’s instructions. Flow cytometry analysis was done on a Fortessa flow 
cytometer (BD, Mountain View, CA, USA). 
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Apoptosis assays 
Cells were cultured in 24-well, flat-bottomed microtiter plates at 105 cells per well in 
RPMI1640–10% FCS or X-VIVO 20 culture medium with or without IL-6 (3ng/mL) and 
appropriate concentration of chemical drugs. After 4 days of culture, cells were washed 
twice in PBS and apoptosis was assayed with PE-conjugated Annexin V labeling (BD 
Biosciences) using a Fortessa flow cytometer (BD) following manufacturer protocols. 
 
RNA sequencing 
HMCLs were cultured for 16 hours with or without 5 µM of UNC-0379, or infected with 
shcontrol or shRNA SETD8 pSIREN vectors for 48h. RNA samples were collected as 
previously described. The RNA sequencing (RNA-seq) library preparation was done 
with 150ng of input RNA using the Illumina TruSeq Stranded mRNA Library Prep Kit. 
Paired-end RNA-seq were performed with Illumina NextSeq sequencing instrument 
(Helixio, Clermont-Ferrand, France). RNA-seq read pairs were mapped to the reference 
human GRCh37 genome using the STAR aligner49. All statistical analyses were 
performed with the statistics software R (version 3.2.3; available from https://www.r-
project.org) and R packages developed by BioConductor project (available from 
https://www.bioconductor.org/)50. The expression level of each gene was summarized 
and normalized using DESeq2 R/Bioconductor package51. Differential expression 
analysis was performed using DESeq2 pipeline. P values were adjusted to control the 
global FDR across all comparisons with the default option of the DESeq2 package. 
Genes were considered differentially expressed if they had an adjusted p-value of 0.05 
and a fold change of 1.5. Pathway enrichment analyses were performed using online 
the curated gene set collection on the Gene Set Enrichment Analysis software 
(http://software.broadinstitute.org/gsea/msigdb/index.jsp)52,53. 
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Gene expression profiling and statistical analyses 
Gene expression data were normalized with the MAS5 algorithm and analyses 
processed with GenomicScape (http://www.genomicscape.com)54 the R.2.10.1 and 
bioconductor version 2.5 programs50. Gene Set Expression Analysis (GSEA) was used 
to identify genes and pathways differentially expressed between populations. Univariate 
and multivariate analysis of genes prognostic for patients’ survival was performed using 
the Cox proportional hazard model. Difference in overall survival between groups of 
patients was assayed with a log-rank test and survival curves plotted using the Kaplan-
Meier method (Maxstat R package)55.  
 
53BP1 Staining-immunofluorescence microscopy 
After deposition on slides using a Cytospin centrifuge, cells were fixed with 4% PFA, 
permeabilized with 0.5% Triton in PBS and saturated with 5% bovine milk in PBS. The 
rabbit anti-53BP1 (Novus Biologicals - Littleton, CO, USA – NB100304) antibody was 
diluted 1/300 in 5% bovine milk in PBS, and deposited on cytospins for 60 minutes at 
room temperature. Slides were washed twice and anti-rabbit alexa 488-conjugated 
antibody (diluted 1/500 in 5% bovine milk in PBS) was added for 60 minutes at room 
temperature. Slides were washed and mounted with Vectashield and 1% DAPI. Images 
and fluorescence were captured with a ZEISS Axio Imager Z2 microscope (X63 
objective) (Oberkochen, Germany), analyzed with Omero (omero.mri.cnrs.fr) server and 
ImageJ software.  
 
Immunoblot analysis. Cells washed with phosphate-buffered saline (PBS) were lysed 
in SDS buffer and boiled at 94°C for 5 minutes. After measuring protein quantity by 
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Bradford, equal amounts of protein were resolved by SDS-PAGE, transferred to a 
nitrocellulose membrane (Millipore) and probed with one of the following antibodies: 
mouse anti-Chk1 (1:1000, abcam), rabbit anti-p21 (1:500, Cell signaling), rabbit anti- 
p53 (1:1000, Cell Signaling), rabbit anti-SETD8 (1:1000, Cell Signaling), mouse anti-β-
actin (1:20000, Sigma), rabbit anti-H2A.X and anti-phospho-H2A.X-Ser139 (1:1000, Cell 
signaling), rabbit anti-H4-K20me1 (1:1000 Cell Signaling), and rabbit anti-Histone H4 
(1:1000, Cell Signaling). Membranes were then incubated with the appropriate 
horseradish peroxidase (HRP)-conjugated secondary antibodies. The immunoreactive 
bands were detected by chemiluminescence (Pierce). 
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FIGURE LEGENDS 
 
Figure 1. SETD8 expression is a prognosis value in MM. (A) SETD8 gene 
expression in BMPCs, patients’ MMCs and HMCLs. Data are MAS5-normalized 
Affymetrix signals (U133 plus 2.0 microarrays).  Statistical difference was assayed using 
a student t-test. (B) Immunoblot analysis of indicated proteins in total lysates from 
normal pre-plasmablasts (pre-PC), MMCs and HMCLs. β-actin and histone H4 were 
used as loading controls. (C) Overall survival and Event Free Survival of newly 
diagnosed MM patients (UAMS-TT2, N=345; and UAMS-TT3, N=158) who’s MMCs 
highly expressed SETD8 gene. The splitting of the patients into two groups according to 
SETD8 expression in MMCs was done using the Maxstat algorithm. (D) SETD8 
expression in 186 patients of the UAMS-TT2 cohort showing Ch1q21 copy number 
aberration. (E) SETD8 expression in MMCs (patients at diagnosis) presenting low, 
medium or high gene expression-based proliferation index (GPI). 
 
Figure 2. SETD8 inhibitor UNC0379 is highly toxic in malignant plasma cells. (A) 
Graphical representation of HMCLs viability upon exposure with various concentration of 
UNC-0379. Color scale represents cell viability, from the highest (blue) to the lowest 
(red) values. Value of IC50 of each HMCL tested is indicated. Data are mean values ± 
standard deviation (SD) of five experiments determined on sextuplet culture wells. (B) 
Immunoblot analysis of SETD8, Histone H4 and H4K20me1 protein levels in XG7 and 
XG25 cells untreated or treated with 3 µM of UNC0379 for 24 hours. (C) Quantitation of 
cell-cycle distribution of control (untreated) and UNC0379-treated XG7 and XG25 
HMCLs 48 hours after treatment. After short-pulse of BrdU incorporation, cell-cycle was 
analyzed by FACS using DAPI and anti-BrdU antibody. Results are representative of 
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three independent experiments. (*) indicates a significant difference compared to control 
cells using a Wilcoxon test for pairs (P ≤ 0.05). (D) Quantitation of apoptosis in control 
and UNC-0379-treated XG7 and XG25 HMCLs by flow cytometry with AnnexinV-PE 
staining and 96h after UNC0379 treatment. Data shown are mean values ± SD of 4 
separate experiments. Statistical analysis was done with a paired t-test. (*) indicates a 
significant difference compared to control cells using a Wilcoxon test for pairs (P ≤ 0.05). 
(E) Percentage of in vitro cultivated primary MM cells (CD138+ tumor cells) and bone 
marrow microenvironment (CD138- non-malignant cells) upon increasing concentration 
of UNC0379 treatment for 4 days. Data shown are mean values of 8 patient samples. (*) 
indicates a significant difference compared to control cells using a Wilcoxon test for 
pairs (P ≤ 0.05). 
 
Figure 3. Gene expression changes in HMCLs upon genetic or pharmacological 
inhibition of SETD8. (A) Molecular signatures of UNC-0379 and shSETD8 
downregulated genes compared to control was investigated using GSEA Database (all 
curated gene sets), and relevant pathways are presented (FDR q-value ≤ 0.05). (B) Bar-
plot representing the fold expression (UNC-0379 condition over control) of genes related 
to (A) chart pathways.  (C) Molecular signatures of UNC-0379 and shSETD8 up-
regulated genes compared to control was investigated using GSEA Database (all 
curated gene sets), and relevant pathways are presented (FDR q-value ≤ 0.05) (D) Bar-
plot representing the fold expression (UNC-0379 condition over control) of genes related 
to (C) chart pathways.  (E) Immunoblot analysis of indicated proteins in total lysates 
from UNC-0379-treated or untreated XG7 HMCL. β-actin and H2A.X were used as 
loading controls. 
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Figure 4. UNC0379 toxicity is independent of P53. (A) Comparison of SETD8 
expression according to HMCLs TP53 status. (B) Comparison of UNC-0379 IC50 (µM) 
according to HMCLs TP53 status. (C) Immunoblot analysis of indicated proteins in total 
lysates from UNC-0379-treated (5µM) or untreated XG7-shControl and XG7-shTP53 
HMCLs. β-actin and H2A.X were used as loading controls. (D) Cell cycle of control and 
48h UNC-0379-treated (5µM) XG7-shTP53 HMCL was analyzed by flow cytometry 
using DAPI, BrdU incorporation and labelling with an anti-BrdU antibody. Results are 
representative of three independent experiments. * indicates a significant difference 
compared to control cells using a Wilcoxon test for pairs (P ≤ 0.05). (E) Apoptosis 
induction in control and UNC-0379-treated (5µM) XG7-shControl and XG7-shTP53 
HMCLs was analyzed with AnnexinV-PE staining by flow cytometry after 96h treatment. 
Data shown are mean values ± SD of 4 separate experiments. Statistical analysis was 
done with a paired t-test. * indicates a significant difference compared to control cells 
using a Wilcoxon test for pairs (P ≤ 0.05). 
 
Figure 5. UNC-0379 treatment sensitizes HMCLs to Melphalan-induced DNA 
damage. (A) Apoptosis induction in XG7 HMCLs sensitive (MelphS) or resistant 
(acquired resistance, MelphR) to Melphalan, after 96h of treatment with Melphalan 
(5µM), UNC-0379-treated (3µM) or the combination of the two drugs. AnnexinV-PE 
staining was analyzed by flow cytometry after 96h treatment. (B) Immunoblot analysis of 
indicated proteins in total lysates from XG7 MelphS or MelphR HMCLs, treated with 
Melphalan (5µM), UNC-0379-treated (3µM) or the combination of the two drugs for 24h. 
β-actin was used as loading control. (C) 53BP1 foci were observed in XG7 MelphS or 
MelphR HMCLs, treated with Melphalan (5µM), UNC-0379-treated (3µM) or the 
combination of the two drugs for 24h. Number of foci per cell was quantified using 
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ImageJ software (mean number of cells counted: 300). Statistical significance between 
conditions was assessed using Student paired t-test (*: pvalue<0.05). (D) Apoptosis 
induction in XG7-shControl and XG7-shTP53 HMCLs after 96h of treatment with 
Melphalan (5µM), UNC-0379-treated (3µM) or the combination of the two drugs. 
AnnexinV-PE staining was analyzed by flow cytometry. 
 
Legends of supplementary Figures: 
 
Supplementary Figure S1: SETD8 expression different subgroup of MM patients. 
Gene expression profiling of MMCs of the patients of UAMS-TT2 cohort were used. PR: 
proliferation, LB: low bone disease, MS: MMSET, HY: hyperdiploid, CD1: Cyclin D1-
Cyclin D3, CD2: Cyclin D1-Cyclin D3, MF: MAF, MY: myeloid. 
 
Supplementary Figure S2: Correlation between SETD8 expression and malignant 
plasma cell labeling index. Plasma cell labeling index was investigated using Brdu 
incorporation and flow cytometry in 101 patients at diagnosis. 
 
Supplementary Figure S3: Gene Signature of MM patients with high SETD8 
expression. GSEA enrichment plots with the absolute enrichment p value and the 
normalized enrichment score of the gene set.  
 
Supplementary Figure S4: SETD8 expression is significantly higher in MM cells of 
patients at relapse (n=47) compared to diagnosis (n=205).  
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Supplementary Figure S5:  Measure of viability and apoptosis in primary murine 5T3vv 
cellular models untreated (cnt) or treated with growing concentrations (from 2.5 to 40 
µM) of UNC0379 for 24 hours.  
 
Supplementary Figure S6: Heatmap of RNA-sequencing rlog expression data. 
Genes deregulated by UNC-0379 and shSETD8 in XG7 and XG25 HMCLs are 
represented. Expression scale shows low expression levels in blue and high expression 
levels in red. 
 
Supplementary Figure S7: Correlation between TP53 and SETD8 expression in 
HMCLs. TP53 and SETD8 expression was obtained from Affymetrix microarrays data 
previously published. 
 
Supplementary Figure S8: Correlation between TP53 expression and drug 
response to UNC-0379 in HMCLs. IC50 was determined using CTG-based growth 
assay, TP53 expression was obtained from Affymetrix microarrays data previously 
published. 
 
Supplementary Figure S9: UNC-0379 induces genomic instability in XG1 p53-
mutant cell line. (A) Immunoblot analysis of indicated proteins in total lysates from 
UNC-0379-treated (5µM) or untreated XG1 HMCL. β-actin and H2A.X were used as 
loading controls. (B) Cell cycle of control and 48h UNC-0379-treated (5µM) XG1 HMCL 
was analyzed by flow cytometry using DAPI, BrdU incorporation and labelling with an 
anti-BrdU antibody. Results are representative of three independent experiments. * 
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indicates a significant difference compared to control cells using a Wilcoxon test for 
pairs (P ≤ 0.05). 
 
Supplementary Figure S10: UNC-0379 induces genomic instability in XG1 p53-
mutant cell line. Comparison of SETD8 and TP53 expression in XG7 HMCL sensitive 
(MelphS) or resistant (MelphR) to Melphalan treatment. 
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